Literature DB >> 11511569

Drug therapy for portal hypertension.

D Lebrec1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11511569      PMCID: PMC1728446          DOI: 10.1136/gut.49.3.441

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  5 in total

Review 1.  Pharmacological treatment of portal hypertension: present and future.

Authors:  D Lebrec
Journal:  J Hepatol       Date:  1998-05       Impact factor: 25.083

2.  Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group.

Authors:  T Poynard; P Calès; L Pasta; G Ideo; J P Pascal; L Pagliaro; D Lebrec
Journal:  N Engl J Med       Date:  1991-05-30       Impact factor: 91.245

3.  Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis.

Authors:  D Lebrec; P De Fleury; B Rueff; H Nahum; J P Benhamou
Journal:  Gastroenterology       Date:  1980-12       Impact factor: 22.682

4.  Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension.

Authors:  P Calés; F Oberti; J L Payen; S Naveau; D Guyader; P Blanc; A Abergel; P Bichard; J M Raymond; V Canva-Delcambre; D Vetter; D Valla; M Beauchant; A Hadengue; B Champigneulle; J P Pascal; T Poynard; D Lebrec
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-07       Impact factor: 2.566

5.  Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis.

Authors:  B Bernard; D Lebrec; P Mathurin; P Opolon; T Poynard
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.